Submission of intimation of allotment of equity shares upon conversion of warrants.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals (formerly Trimurthi Limited) has allotted 15,45,000 equity shares at Rs. 20 each (face value Rs. 10 + premium Rs. 10) following the conversion of an equal number of warrants on a preferential basis. The company received Rs. 2.31 crore as the remaining 75% of the issue price from 8 allottees, including promoter group members (Narahari Belide, Vupparapalli Chandrasekhar Reddy) and non-promoter strategic investors. With this allotment, paid-up equity capital rose from Rs. 12.93 crore (1.29 crore shares) to Rs. 14.48 crore (1.44 crore shares). This is part of a larger 1.5 crore warrant issuance originally made on January 10, 2025, of which 29.85 lakh warrants were already converted earlier.
This is a routine conversion of warrants into equity shares that was already pre-approved and partially executed earlier. It results in modest equity dilution (~19% increase in share count) but brings in additional capital of Rs. 2.31 crore. Shareholders should note the steady dilution from repeated warrant conversions, though no immediate negative price impact is expected as the issue price was pre-set.